sept 15- www.otcmarkets.com. Sept 30th - 10k. Sept is the month we will all see exactly what this mgmt team and BOD did here . DILUTION DILUTION DILUTION the only question is how much? Shareholders need to see. Our Boys and Girls have calls into Zonis, Woundclot and Centri. Our boys and girls like to channel check- not finding much. 714- Can you help us here and dust the cobwebs off these businesses and enlighten us? Also why hasn't Dr. Drew been issued his 138 mill shares? He earned them contractually didn't he? TRANSPARENCY is what we strive for . Raising capital is a material event for SNDD- Why no 8k's ? Can anyone tell 714 and the rest of the shareholders what an " Interest Free EXchange is" ? What is FREE about an " Interest Free Exchange" ? Please help our boys and girls. MORE DISPUTES : SEE BELOW SEE BELOW SEE bELOW In September 2018, the Company acquired the exclusive license rights to certain medical device technology for $450,000, plus a broker’s fee of $17,500. Under the terms of the license agreement, the Company has paid $25,000 plus the first of a total twenty quarterly payments of $21,250. Any remaining payments become immediately payable upon the receipt of final approval by the FDA of devices related to the technology. Additionally, the Company agreed to pay a consulting fee of $1,000 per month for sixty months. The broker’s fee was paid through the issuance of 14 million shares of the Company’s common stock. The quarterly payments and the consulting fee have been suspended at the present time as the Company and the seller negotiate certain disputes related to representations made by the seller at the time the Company acquired the rights. The ultimate date and resolution of this negotiation cannot be estimated at this time. As a result, the Company has included all of the future payments under the original agreement as noncurrent in the accompanying March 31, 2020 and June 30, 2019 consolidated balance sheets.
